Creathor’s therapeutic options

Creathor Venture expects its fourth and largest fund will allow the pan-European VC to invest in therapeutics companies previously considered too capital-intensive.

Karlheinz Schmelig told BioCentury Creathor Venture IV, a mixed IT and life sciences fund, is targeting €120 million ($132.6 million), 50% more than the €80 million Creathor Venture III fund that closed in 2011. Creathor has €165 million ($182.3 million) under management in its first three funds. ...